

22 November 2022

List of NCA's participating in the Simultaneous National Scientific Advice (SNSA) pilot phase 2

For SNSA requests/inquiries the contact details of all NCA's participating in the SNSA pilot phase 2 can be found in the list below:

| No. | Country | Agency | Contact info | Leading/ participating NCA | Observer Role |
|-----|---|-----------|--|-------------------------------|---------------|
| 1 |  Austria | AGES/BASG | scientificadvice @basg.gv.at innovation@ages.at | X | |
| 2 |  Belgium | FAMHP | innovationoffice@fagg-afmp.be sta-wta@fagg-afmps.be | X | |
| 3 |  Czechia | SÚKL | innovation@sukl.cz | X | |
| 4 |  Denmark | DKMA | Nationalscientificadvice@dkma.dk innovation@dkma.dk | X | |
| 5 |  Finland | FIMEA | innovation.office@fimea.fi | X | |
| 6 |  France | ANSM | innovation@ansm.sante.fr | X | |
| 7 |  Germany | PEI | innovation@pei.de | X | |
| 8 |  Hungary | OGYEI | tanacsadas@ogyei.gov.hu | X | |
| 9 |  Ireland | HPRA | innovationoffice@hpra.ie scientificadvice@hpra.ie | X | |
| 10 |  Italy | AIFA | Innovation.office@aifa.gov.it | | X |
| 11 |  Netherlands | MEB | nationalscientificadvice@cbg-meb.nl | X | |
| 12 |  Netherlands | CCMO | ccmo@ccmo.nl | | X |
| 13 |  Norway | NOMA | Ask-us@legemiddelverket.no | X | |
| 14 |  Poland | URPL | snsa@urpl.gov.pl innowacjaPL@urpl.gov.pl | X | |
| 15 |  Portugal | INFARMED | garc@infarmed.pt | X | |
| 16 |  Sweden | MPA | innovationoffice@lakemedelsverket.se RIC@lakemedelsverket.se | X | |
| 17 |  Spain | AEMPS | ascina@aemps.es innov_spain@aemps.es | X | |

- (11) The Medicines Evaluation Board (MEB) is the Dutch competent authority responsible for assessing medicinal products (eg. scientific advice, marketing authorisation applications) and for monitoring the risk of medicines for human use, and for promoting the proper use of medicines. The MEB is however not responsible for the evaluation of clinical trials applications.
- (12) The Central Committee on Research Involving Human Subjects (CCMO) is the Dutch competent authority responsible for the evaluation of clinical trial applications.

Remark:

The NCA's listed above have agreed to actively participate in the handling of the incoming SNSA pilots either as coordinating / participating NCA or as observer. In either cases, the involvement is on a voluntary, opting-in basis (i.e. pending the available expertise and capacity at NCA level). The list of NCA's participating in the SNSA pilot phase 2 is subject to change and will be regularly updated as additional NCA's may consider participating in the course of the pilot.